|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2010-2-9
|
|
pubmed:abstractText |
Discrepancies exist regarding the impact of neoadjuvant hormone therapy (NHT) on the risk of all-cause mortality (ACM) in men who receive brachytherapy for localized prostate cancer. Therefore, the objective of the current study was to examine the effect of NHT on the risk of ACM in men with prostate cancer who receive with brachytherapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
116
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
837-42
|
|
pubmed:meshHeading |
pubmed-meshheading:20052734-Age Factors,
pubmed-meshheading:20052734-Aged,
pubmed-meshheading:20052734-Androgen Antagonists,
pubmed-meshheading:20052734-Antineoplastic Agents, Hormonal,
pubmed-meshheading:20052734-Brachytherapy,
pubmed-meshheading:20052734-Cause of Death,
pubmed-meshheading:20052734-Combined Modality Therapy,
pubmed-meshheading:20052734-Humans,
pubmed-meshheading:20052734-Male,
pubmed-meshheading:20052734-Neoadjuvant Therapy,
pubmed-meshheading:20052734-Prostatic Neoplasms,
pubmed-meshheading:20052734-Retrospective Studies
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Mortality in men with localized prostate cancer treated with brachytherapy with or without neoadjuvant hormone therapy.
|
|
pubmed:affiliation |
Department of Radiation Oncology, Harvard Radiation Oncology Program, Boston, Massachusetts 02115, USA.
|
|
pubmed:publicationType |
Journal Article
|
